Karyopharm Therapeutics (KPTI) PT Raised to $22 at Wedbush, Following Announcement Of FDA Approval

December 21, 2020 2:37 PM EST
Get Alerts KPTI Hot Sheet
Price: $8.55 --0%

Rating Summary:
    14 Buy, 1 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 26 | New: 41
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Wedbush analyst David Nierengarten raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $22.00 (from $21.00) while maintaining a Neutral rating.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst PT Change

Related Entities

FDA